Literature DB >> 1860055

Tumor necrosis factor facilitates regeneration of injured central nervous system axons.

M Schwartz1, A Solomon, V Lavie, S Ben-Bassat, M Belkin, A Cohen.   

Abstract

The results of this study attribute to tumor necrosis factor (TNF) a role in regeneration of injured mammalian central nervous system (CNS) axons which grow into their own degenerating environment. This is the first time that a specific factor involved in axonal regeneration has been identified. The axonal environment is occupied mostly by glia cells, i.e., astrocytes and oligodendrocytes. Previous studies have shown that mature oligodendrocytes are inhibitory to axonal growth. Therefore, it seemed likely that application of a factor such as TNF, which has been shown to be cytotoxic to oligodendrocytes, would contribute to the creation of permissive conditions for axonal regeneration. In the present work, injured adult rabbit optic nerves were treated with human recombinant TNF (rhTNF). As a result, abundant newly growing axons (circa 9000, about 4% of the total estimated number of axons in an intact adult rabbit) were observed traversing the site of injury.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860055     DOI: 10.1016/0006-8993(91)91309-o

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  Purkinje cell survival and axonal regeneration are age dependent: an in vitro study.

Authors:  I Dusart; M S Airaksinen; C Sotelo
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

2.  Astrogliosis in the neonatal and adult murine brain post-trauma: elevation of inflammatory cytokines and the lack of requirement for endogenous interferon-gamma.

Authors:  M Rostworowski; V Balasingam; S Chabot; T Owens; V W Yong
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

3.  Identification of an interleukin 2-like substance as a factor cytotoxic to oligodendrocytes and associated with central nervous system regeneration.

Authors:  S Eitan; R Zisling; A Cohen; M Belkin; D L Hirschberg; M Lotan; M Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

4.  Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.

Authors:  W K Kim; Y Kan; D Ganea; R P Hart; I Gozes; G M Jonakait
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

5.  Upregulation of tumor necrosis factor alpha transport across the blood-brain barrier after acute compressive spinal cord injury.

Authors:  W Pan; A J Kastin; R L Bell; R D Olson
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

6.  Intrinsic changes in developing retinal neurons result in regenerative failure of their axons.

Authors:  D F Chen; S Jhaveri; G E Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

7.  Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia.

Authors:  E Tarkowski; K Blennow; A Wallin; A Tarkowski
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

Review 8.  Cytokine transport across the injured blood-spinal cord barrier.

Authors:  Weihong Pan; Abba J Kastin
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Intrathecal inflammation precedes development of Alzheimer's disease.

Authors:  E Tarkowski; N Andreasen; A Tarkowski; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

10.  A 5-year longitudinal study of the relationships between stress, coping, and immune cell beta(2)-adrenergic receptor sensitivity.

Authors:  Brent T Mausbach; Kirstin Aschbacher; Paul J Mills; Susan K Roepke; Roland von Känel; Thomas L Patterson; Joel E Dimsdale; Michael G Ziegler; Sonia Ancoli-Israel; Igor Grant
Journal:  Psychiatry Res       Date:  2008-08-16       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.